Urinary Bladder, Overactive
Conditions
Brief summary
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
Interventions
BIOLOGICALonabotulinumtoxinA
onabotulinumtoxinA (BOTOX®)100 to 200 U
Sponsors
Allergan
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with documented idiopathic OAB diagnosis * Patient was treated with 100-200U of BOTOX® for OAB * Urodynamics assessment within prior to first BOTOX® injection.
Exclusion criteria
* Patient had received botulinum toxin formulations other than BOTOX® in the bladder * Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX® | Pre-BOTOX® Injection (Baseline) | VE was calculated as the ratio of voided volume to the total bladder capacity. |
| Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX® | 12 Weeks | — |
Countries
United States
Outcome results
None listed